<unk>  is a rare primary brain carcinoma. It is a diffusely infiltrating neuroepithelial tumor, which involves at least three<unk> l lobes and occasionally infratentorial structures or the spinal cord. The brain architecture is commonly preserved, with neurons being spared.<unk>  is classified as glial tumors of the central nervous system. Recent data does not classify this tumor growth as a primary diagnosis, instead its name is used to describe a special pattern of diffuse and extensive growth of glioma cells, involving multiple lobes of the brain. Microscopic histopathological examination may reveal diffuse proliferation of immature glial elements resembling astrocytes, oligodendroglia, or undifferentiated cells with cytologic and nuclear atypia, calcifications, microcysts, and mitotic figures without the presence of any necrosis or microvascular proliferation. Gross pathology of<unk>  is characterized by a diffuse astrocytic growth pattern involving at least three<unk> l lobes and bilateral involvement of the<unk> l hemispheres, deep gray matter, brainstem, or cerebellum. Symptoms include: headache, nausea, vomiting, seizure, loss of balance, memory loss, personality changes, cognitive problems, confusion, diplopia, difficulty in swallowing, difficulty in speech, motor weakness, and facial numbness. Imaging through a head CT scan can show an isodense and hypoattenuated mass with ill-defined asymmetry and lack of mass effect. While on brain MRI,<unk>  is characterized by bilateral and diffuse infiltrative tumor which is isointense or hypointense on T1-weighted images and hyperintense on T2-weighted and FLAIR images. Other imaging studies for<unk>  include MR spectroscopy, MR perfusion, PET scan, and bone scan. Radiotherapy and chemotherapy are recommended among all patients who develop<unk> . Temozolomide and PCV 3 combination chemotherapy are the preferred drugs for the treatment of high-grade and low-grade<unk> , respectively. Supportive therapy for<unk>  includes anticonvulsants and corticosteroids. Surgery is not the first-line treatment option for patients with<unk> .
Gliomatosis cerebri
Meningism
Brain abscess
Meninges
Temporal arteritis
Neoplastic meningitis
Subarachnoid hemorrhage
Limbic encephalitis